Kymera Therapeutics (KYMR) Operating Leases (2019 - 2025)
Historic Operating Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $68.4 million.
- Kymera Therapeutics' Operating Leases fell 704.28% to $68.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.4 million, marking a year-over-year decrease of 704.28%. This contributed to the annual value of $72.4 million for FY2024, which is 597.83% down from last year.
- Kymera Therapeutics' Operating Leases amounted to $68.4 million in Q3 2025, which was down 704.28% from $69.8 million recorded in Q2 2025.
- Kymera Therapeutics' 5-year Operating Leases high stood at $77.0 million for Q4 2023, and its period low was $12.1 million during Q4 2022.
- Over the past 5 years, Kymera Therapeutics' median Operating Leases value was $68.4 million (recorded in 2025), while the average stood at $47.3 million.
- As far as peak fluctuations go, Kymera Therapeutics' Operating Leases tumbled by 815.18% in 2022, and later surged by 53418.41% in 2023.
- Quarter analysis of 5 years shows Kymera Therapeutics' Operating Leases stood at $13.2 million in 2021, then dropped by 8.15% to $12.1 million in 2022, then soared by 534.18% to $77.0 million in 2023, then decreased by 5.98% to $72.4 million in 2024, then decreased by 5.49% to $68.4 million in 2025.
- Its last three reported values are $68.4 million in Q3 2025, $69.8 million for Q2 2025, and $71.2 million during Q1 2025.